当前位置: 首页 >> 检索结果
6901. Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial.
作者: Raj R Makkar.;Wen Cheng.;Ron Waksman.;Lowell F Satler.;Tarun Chakravarty.;Mark Groh.;William Abernethy.;Mark J Russo.;David Heimansohn.;James Hermiller.;Stephen Worthley.;Bassem Chehab.;Mark Cunningham.;Ray Matthews.;Ravi K Ramana.;Gerald Yong.;Carlos E Ruiz.;Chunguang Chen.;Federico M Asch.;Mamoo Nakamura.;Hasan Jilaihawi.;Rahul Sharma.;Sung-Han Yoon.;Augusto D Pichard.;Samir Kapadia.;Michael J Reardon.;Deepak L Bhatt.;Gregory P Fontana.
来源: Lancet. 2020年396卷10252期669-683页
Randomised trial data assessing the safety and efficacy of the self-expanding intra-annular Portico transcatheter aortic valve system (Abbott Structural Heart, St Paul, MN, USA) compared with any commercially available valves are needed to compare performance among designs.
6902. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
作者: Adrian Murray Brunt.;Joanne S Haviland.;Duncan A Wheatley.;Mark A Sydenham.;Abdulla Alhasso.;David J Bloomfield.;Charlie Chan.;Mark Churn.;Susan Cleator.;Charlotte E Coles.;Andrew Goodman.;Adrian Harnett.;Penelope Hopwood.;Anna M Kirby.;Cliona C Kirwan.;Carolyn Morris.;Zohal Nabi.;Elinor Sawyer.;Navita Somaiah.;Liba Stones.;Isabel Syndikus.;Judith M Bliss.;John R Yarnold.; .
来源: Lancet. 2020年395卷10237期1613-1626页
We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction regimen after primary surgery for early breast cancer. Here, we present 5-year results of the FAST-Forward trial.
6907. Solidarity in the wake of COVID-19: reimagining the International Health Regulations.
作者: Allyn L Taylor.;Roojin Habibi.;Gian Luca Burci.;Stephanie Dagron.;Mark Eccleston-Turner.;Lawrence O Gostin.;Benjamin Mason Meier.;Alexandra Phelan.;Pedro A Villarreal.;Alicia Ely Yamin.;Danwood Chirwa.;Lisa Forman.;Gorik Ooms.;Sharifah Sekalala.;Steven J Hoffman.
来源: Lancet. 2020年396卷10244期82-83页 6910. New directions in the treatment of opioid withdrawal.
The treatment of opioid withdrawal is an important area of clinical concern when treating patients with chronic, non-cancer pain, patients with active opioid use disorder, and patients receiving medication for opioid use disorder. Current standards of care for medically supervised withdrawal include treatment with μ-opioid receptor agonists, (eg, methadone), partial agonists (eg, buprenorphine), and α2-adrenergic receptor agonists (eg, clonidine and lofexidine). Newer agents likewise exploit these pharmacological mechanisms, including tramadol (μ-opioid receptor agonism) and tizanidine (α2 agonism). Areas for future research include managing withdrawal in the context of stabilising patients with opioid use disorder to extended-release naltrexone, transitioning patients with opioid use disorder from methadone to buprenorphine, and tapering opioids in patients with chronic, non-cancer pain.
6912. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
Tranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding.
|